Business Context and Reporting Period
This Form 8-K is a current report filed by Unicycive Therapeutics, Inc. (UNCY) on April 6, 2026. The Company is a Delaware corporation headquartered in Mountain View, California, and its common stock trades on the Nasdaq Capital Market. The filing addresses a specific corporate governance event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of a director:
- Resignation: Gaurav Aggarwal resigned from the Board of Directors on April 6, 2026.
- Reason: The resignation was not the result of any disagreement with the Company, its management, or the Board regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No new risks, contingencies, or unusual items were disclosed in this report. The Company expressed gratitude to Dr. Aggarwal for his service.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Dr. Aggarwal's resignation.
- Check for any subsequent filings regarding the appointment of a replacement director.
- Review the Company's most recent 10-Q or 10-K for up-to-date financial metrics, as this 8-K does not contain them.